2MURO K,BOKU N,SHIMADA Y,et al.Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a randomised phase 2/3 non-inferiority study[J].Lancet Oncol,2010,11(9):853-860.
3OOSTENDORP L J,STALMEIER P F,PASKER-DE J P C,et al.Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer[J].Anticancer Drugs,2010,21(8):749-758.
4FUCHS C S,MARSHALL J,BARRUECO J.Randomized,controlled trial of irinotecan plus infusional,bolus,or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer:results from the BICC-C study[J].J Clin Oncol,2007,24(24):4779-4786.
5FUJITA K,SPARREBOOM A.Pharmacogenetics of irinotecan disposition and toxicity:a review[J].Curr Clin Pharmacol,2010,5(3):209-217.
1JAFFE N.Osteosarcoma:review of the past,impact on the future.the american experience[J].Cancer Treat Res,2010,152:239-262.
2GRIMER R J.Surgical options for children with osteosa-rcoma[J].Lancet Oncol,2005,6(2):85-92.
3LEWIS I J,NOOIJ M A,WHELAN J,et al.Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy:a randomized phase III trial of the European Osteosarcoma Intergroup[J].J Natl Cancer Inst,2007,99(2):112-128.
4BAKER P D,MORZORATI S L,ELLETT M L.The patho-physiology of chemotherapy-induced nausea and vomiting[J].Gastroenterol Nurs,2005,28(6):469-480.
5LIEKWEG A,WESTFELD M,JAEHDE U.From oncology pharmacy to pharmaceutical care:new contributions to multidisciplinary cancer care[J].Support Care Cancer,2004,12(2):73-79.
10US Department of Health and Human Services,National Institutes of Health,National Cancer Institute.Common terminology criteria for adverse events(ctcae)version 4.0[S].2009-05.
